Friday, March 4, 2016, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.30 to $2,750,000.00.

Highlighted Stocks Traded by Insiders:

Extended Stay America (STAY) - FREE Research Report

Kussell William A, who is Director at Extended Stay America, sold 40,000 shares at $14.76 on March 4, 2016. Following this transaction, the Director owned 49,898 shares meaning that the stake was reduced by 44.49% with the 40,000-share transaction.

The shares most recently traded at $14.90, up $0.14, or 0.93% since the insider transaction.

The average volume for Extended Stay America has been 880,500 shares per day over the past 30 days. Extended Stay America has a market cap of $3.1 billion and is part of the services sector and leisure industry. Shares are down 6.79% year-to-date as of the close of trading on Friday.

Extended Stay America, Inc. develops, owns, and operates hotels in the United States and Canada. The stock currently has a dividend yield of 4.51%. The company has a P/E ratio of 36.8. Currently, there are 3 analysts who rate Extended Stay America a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STAY - FREE

TheStreet Quant Ratings

rates Extended Stay America as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally disappointing historical performance in the stock itself, generally high debt management risk and weak operating cash flow. Get the full

Extended Stay America Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Southwest Gas (SWX) - FREE Research Report

Janov Edward A, who is SVP/Corporate Development at Southwest Gas, sold 1,200 shares at $61.10 on March 4, 2016. Following this transaction, the SVP/Corporate Development owned 33,920 shares meaning that the stake was reduced by 3.42% with the 1,200-share transaction.

The shares most recently traded at $62.42, up $1.32, or 2.11% since the insider transaction. Historical insider transactions for Southwest Gas go as follows:

  • 4-Week # shares sold: 800
  • 12-Week # shares sold: 1,600
  • 24-Week # shares sold: 3,000

The average volume for Southwest Gas has been 239,200 shares per day over the past 30 days. Southwest Gas has a market cap of $2.9 billion and is part of the utilities sector and utilities industry. Shares are up 14.18% year-to-date as of the close of trading on Friday.

Southwest Gas Corporation purchases, distributes, and transports natural gas in Arizona, Nevada, and California. The company operates in two segments, Natural Gas Operations and Construction Services. The stock currently has a dividend yield of 2.92%. The company has a P/E ratio of 22.0. Currently, there are 3 analysts who rate Southwest Gas a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWX - FREE

TheStreet Quant Ratings

rates Southwest Gas as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, solid stock price performance and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Southwest Gas Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Macrogenics (MGNX) - FREE Research Report

Costa Paulo F, who is Director at Macrogenics, bought 10,000 shares at $17.20 on March 4, 2016. Following this transaction, the Director owned 59,435 shares meaning that the stake was boosted by 20.23% with the 10,000-share transaction.

The shares most recently traded at $18.76, up $1.56, or 8.32% since the insider transaction. Historical insider transactions for Macrogenics go as follows:

  • 4-Week # shares sold: 1,921
  • 12-Week # shares sold: 1,921
  • 24-Week # shares sold: 11,271

The average volume for Macrogenics has been 293,500 shares per day over the past 30 days. Macrogenics has a market cap of $588.1 million and is part of the health care sector and drugs industry. Shares are down 39.91% year-to-date as of the close of trading on Friday.

MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. Currently, there are 5 analysts who rate Macrogenics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MGNX - FREE

TheStreet Quant Ratings

rates Macrogenics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, unimpressive growth in net income and generally disappointing historical performance in the stock itself. Get the full

Macrogenics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.